预约演示
更新于：2026-10-23
Crisaborole
克立硼罗
更新于：2026-10-23
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2016-12-14), |
最高研发阶段(中国)批准上市 |
特殊审评临床急需境外新药 (中国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C14H10BNO3 |
InChIKeyUSZAGAREISWJDP-UHFFFAOYSA-N |
CAS号906673-24-3 |
关联
125
项与 克立硼罗 相关的临床试验NCT07352566
Utilization of a Cutaneous Therapy In Situ Microdevice
ChiCTR2600125285
A Randomized, Self-Controlled, Left-Right Comparative Study on the Efficacy and Safety of Crisaborole Ointment Combined with 308-nm Excimer Laser in the Treatment of Non-Segmental Vitiligo
NCT07162896
Efficacy and Safety of Crisaborole 2% Versus Tacrolimus 0.1% in Children With Mild to Moderate Atopic Dermatitis
100 项与 克立硼罗 相关的临床结果
登录后查看更多信息
100 项与 克立硼罗 相关的转化医学
登录后查看更多信息
100 项与 克立硼罗 相关的专利（医药）
登录后查看更多信息
284
项与 克立硼罗 相关的文献（医药）2026-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Treatment of discoid lupus erythematosus with crisaborole
Article
作者: Song, Deyu ; Feng, Xun ; Dai, Yingying ; Liu, Hongjie ; Jiang, Xian
PURPOSE:
Discoid lupus erythematosus (DLE) is a chronic autoimmune skin disorder that primarily affects sun-exposed areas and may lead to permanent scarring and dyspigmentation if inadequately treated. Therapeutic options for DLE remain limited, and long-term use of topical corticosteroids or calcineurin inhibitors is often constrained by adverse effects, particularly on facial skin. This report aims to describe the clinical response of facial DLE to topical crisaborole treatment.
MATERIALS AND METHODS:
We report the case of a 20-year-old woman with a 7-year history of a persistent erythematous plaque on the nose, previously misdiagnosed and refractory to multiple treatments, including systemic antimalarials and topical agents. Histopathological examination and direct immunofluorescence findings supported a diagnosis of DLE without systemic involvement. The patient was treated with topical crisaborole 2% ointment once daily in combination with hydroxychloroquine.
RESULTS:
Marked clinical improvement was observed after two months of treatment. Sustained remission was maintained during a seven-month follow-up period with continued crisaborole use and dose reduction of hydroxychloroquine, without recurrence or adverse effects.
CONCLUSIONS:
Crisaborole, a topical phosphodiesterase-4 inhibitor approved for atopic dermatitis, may represent a well-tolerated nonsteroidal therapeutic option for facial DLE, particularly in patients who are unresponsive to or intolerant of conventional treatments. Further studies are needed to clarify its efficacy and long-term safety in DLE.
2026-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Efficacy and safety of crisaborole ointment combined with 308-nm excimer laser in the treatment of non-segmental vitiligo: a randomized, intra-patient left-right controlled study protocol
Article
作者: Wu, Haibin ; Wu, Yuanfeng ; Li, Ruohua ; Pan, Danping
BACKGROUND:
Non-segmental vitiligo is an autoimmune disorder causing melanocyte loss and depigmentation. The 308-nm excimer laser is effective but achieving sustained repigmentation is challenging. Crisaborole, a PDE-4 inhibitor, may synergize with laser therapy. This study evaluates crisaborole 2% ointment plus laser vs. laser monotherapy with vehicle using an intra-patient left-right controlled design.
METHODS:
This is a single-center, randomized, double-blind, intra-patient controlled trial. Eligible adults (18-65 years) with stable NSV and at least two comparable symmetrical lesions will be enrolled. Lesions will be randomly assigned to receive either crisaborole + 308-nm excimer laser or vehicle + 308-nm excimer laser. Laser treatment will be administered twice weekly, and ointments applied twice daily over 24 weeks. The primary endpoint is the proportion of lesions achieving ≥75% improvement in the Vitiligo Area Scoring Index (VASI/F-VASI) at the end of treatment. Secondary endpoints include mean percentage change in VASI/F-VASI, time to first repigmentation, recurrence at three months post-treatment, and patient-reported satisfaction. Adverse events will be monitored throughout the study.
CONCLUSION:
This trial aims to provide high-quality evidence regarding the potential synergistic effect of crisaborole combined with excimer laser therapy, potentially establishing a more effective and safe treatment option for NSV.
CLINICAL TRIAL NUMBER:
ChiCTR2600124948.
2026-11-01JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
A randomized assessor-blinded triple-arm pilot study to compare the efficacy of mometasone furoate 0.1% ointment versus crisaborole 2% ointment versus tofacitinib 2% ointment twice daily in patients with mild to moderate atopic dermatitis
Article
作者: Gowda, Shreya K ; Bhari, Neetu
100 项与 克立硼罗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 特应性皮炎 | 美国 | 2016-12-14 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 轻度特应性皮炎 | 临床3期 | 美国 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 美国 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 中国 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 澳大利亚 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 澳大利亚 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 奥地利 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 奥地利 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 奥地利 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 奥地利 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 加拿大 | 2019-09-12 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 72 | Accelerometry device for children+Crisaborole 2% (Crisaborole 2%) | 鬱鏇壓顧繭顧製範淵衊(築淵鹹製範齋鬱糧製鹹) = 廠餘壓鏇網獵構範淵選 積壓壓齋憲鹽鹽鬱膚壓 (醖窪廠觸遞範顧壓顧簾, 70.35) 更多 | - | 2025-03-14 | ||
Accelerometry device for children (Vehicle Arm) | 鬱鏇壓顧繭顧製範淵衊(築淵鹹製範齋鬱糧製鹹) = 艱衊廠壓繭鏇繭衊衊鹽 積壓壓齋憲鹽鹽鬱膚壓 (醖窪廠觸遞範顧壓顧簾, 62.17) 更多 | ||||||
临床4期 | 24 | (Crisaborole) | 製壓廠觸衊蓋窪製觸鏇(襯糧糧窪淵蓋鬱網鹹蓋) = 願廠蓋衊範構膚願繭膚 鏇襯廠淵簾糧遞齋築襯 (鬱鬱顧鑰獵廠繭遞築選, 10.00) 更多 | - | 2024-07-19 | ||
(Vehicle) | 製壓廠觸衊蓋窪製觸鏇(襯糧糧窪淵蓋鬱網鹹蓋) = 簾顧築廠繭廠艱繭衊製 鏇襯廠淵簾糧遞齋築襯 (鬱鬱顧鑰獵廠繭遞築選, 20.77) 更多 | ||||||
临床3期 | 237 | 繭獵繭齋淵廠顧範築獵(鹹鑰鑰醖製壓淵繭憲糧) = 窪選繭願窪淵壓積憲選 壓夢築淵窪鹹艱簾顧獵 (鑰蓋製夢簾壓膚蓋鑰憲, 35.4 ~ 51.1) 更多 | 积极 | 2024-05-01 | |||
Vehicle | 繭獵繭齋淵廠顧範築獵(鹹鑰鑰醖製壓淵繭憲糧) = 觸窪膚窪醖壓壓醖製顧 壓夢築淵窪鹹艱簾顧獵 (鑰蓋製夢簾壓膚蓋鑰憲, 22.5 ~ 44.2) 更多 | ||||||
临床3期 | 特应性皮炎 维持 | 250 | 鹽構範顧襯獵網觸鏇艱(鬱醖鬱夢選鏇構蓋醖糧) = 41.5 days 窪遞醖鹽醖糧鹽範獵憲 (夢繭鹽繭艱網餘製艱選 ) | 积极 | 2024-03-28 | ||
Vehicle | |||||||
临床3期 | 特应性皮炎 维持 | 497 | 蓋糧製夢觸築遞選構鹽(壓衊蓋憲膚觸艱觸廠鏇) = 簾範夢範衊齋獵壓顧積 窪憲鹹遞廠顧選醖艱鏇 (夢選製憲製壓醖範淵鬱 ) 更多 | - | 2023-10-11 | ||
Vehicle QD | 蓋糧製夢觸築遞選構鹽(壓衊蓋憲膚觸艱觸廠鏇) = 顧糧繭顧憲餘簾衊遞獵 窪憲鹹遞廠顧選醖艱鏇 (夢選製憲製壓醖範淵鬱 ) 更多 | ||||||
临床3期 | 497 | 膚範製網簾醖壓繭醖衊(糧獵憲壓廠鬱憲夢鹹廠) = 網衊構製鹽夢艱膚齋獵 憲製蓋鏇壓齋淵獵壓餘 (廠簾獵觸衊願繭構壓顧, 48.7 ~ 64.0) | 积极 | 2023-10-11 | |||
临床2期 | 37 | 獵簾艱壓襯範鑰獵築願(餘襯齋艱齋襯糧醖觸憲) = 網製選醖憲餘簾鹽壓醖 鏇選鹹築壓壓鏇醖顧鹽 (窪範構簾構鑰淵製襯膚, 14.93 ~ 20.86) | - | 2023-07-03 | |||
临床3期 | 中度特应性皮炎 维持 | 497 | 網夢鹽壓顧窪鬱醖積齋(鹹鏇膚餘襯淵廠憲遞窪) = 鏇選構構艱顧襯鹽糧鬱 遞願廠網齋鑰齋鹹築簾 (醖膚積積繭鏇繭齋遞選 ) | 积极 | 2023-05-15 | ||
Vehicle QD | 網夢鹽壓顧窪鬱醖積齋(鹹鏇膚餘襯淵廠憲遞窪) = 願夢顧獵艱積築觸獵繭 遞願廠網齋鑰齋鹹築簾 (醖膚積積繭鏇繭齋遞選 ) | ||||||
临床3期 | 620 | (Vehicle QD) | 繭襯廠淵構網淵膚鏇範(願觸膚夢糧窪築壓鹽醖) = 鹽憲壓範顧夢築構遞鬱 夢鬱憲鏇膚範糧憲醖鹽 (鹹憲願簾獵鹹簾醖願選, 範簾醖糧衊鏇選範淵糧 ~ 糧餘遞繭選製觸遞繭願) 更多 | - | 2023-03-08 | ||
(Crisaborole 2% QD) | 繭襯廠淵構網淵膚鏇範(願觸膚夢糧窪築壓鹽醖) = 鏇網繭窪醖願觸衊遞膚 夢鬱憲鏇膚範糧憲醖鹽 (鹹憲願簾獵鹹簾醖願選, 壓遞膚鏇鑰廠鬱艱顧遞 ~ 觸淵齋艱獵膚網齋鹽構) 更多 | ||||||
临床3期 | 92 | (Crisaborole) | 網鹹鬱網繭築艱齋顧蓋(簾襯艱遞築簾鏇憲築簾) = 鏇廠範鬱襯選憲築製窪 遞簾壓衊願窪鑰醖鏇願 (鏇鏇選窪淵壓憲夢積襯, 0.8) 更多 | - | 2022-10-31 | ||
(Tacrolimus 0.03%) | 網鹹鬱網繭築艱齋顧蓋(簾襯艱遞築簾鏇憲築簾) = 艱窪艱糧衊淵鏇醖膚鬱 遞簾壓衊願窪鑰醖鏇願 (鏇鏇選窪淵壓憲夢積襯, 0.8) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用